![Minerva Neurosciences, Inc. logo](MINERVA NEUROSCIENCES, INC.)

Minerva Neurosciences, Inc.
Investor Relations Department
1601 Trapelo Road
Suite 284
Waltham, MA 02451
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: NERV

Last Trade:	5.95
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.15 ⬇ (- 2.459%)
Day Range	5.85 - 6.30
52-Week Range	6.10 - 14.92
Volume	137,043

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is... (more)

Stock Performance

Press Releases   [View all]

Aug 3, 2017
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates

Jul 31, 2017
American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia

Jul 27, 2017
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017

Jul 24, 2017
Minerva Neurosciences Announces Departure of Directors

Jul 5, 2017
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Financials   [View all]

Second Quarter Financial Results

Mar 13, 2017
Annual Report (10-K)

Apr 18, 2017
Proxy Statement (DEF 14A)

Aug 3, 2017
Quarterly Report (10-Q)

May 4, 2017
Quarterly Report (10-Q)

Nov 3, 2016
Quarterly Report (10-Q)